Global leader in liquid biopsy

Discovery of tumor-specific DNA methylation markers
in the blood makes early treatment possible.

With capabilities in marker discovery, assay development and
analytical and clinical validation, we provide total solution as a global diagnostic company

Products

Methyl Series

LepiDyne is developing a methylation-based
in vitro diagnostic device.

MethyLiverDx

Liver cancer blood early diagnosis kit

MethyLiverMT

Liver Cancer Treatment Monitoring Kit

MethyLiverPro

Liver cancer tissue treatment prediction kit (companion diagnosis)

LepiMag^TM
Blood Cell-Free DNA
Extraction Kit

cfDNA Extraction Kit

Technology

Core Technology

LepiDyne has a liquid biopsy–suitable biomarker discovery pipeline, a detection method, and optimized reagents.

Biomarker Discovery Technology

We used multiomics big data and machine learning to establish a DNA methylation biomarker discovery pipeline. We are continuously searching for new cancer biomarkers.

LepiMA: A cancer-specific methylation marker discovery platform

Liquid Epiallele Melting Analyzer
The platform complements the previous methylation detection method and is optimized for liquid biopsy. The melting temperature differences due to methylation determine the ratio between the methylated and non-methylated product and reflect the tumor heterogeneity.

Company

LepiDyne

lepiDYNE

Global leader in liquid biopsy

Discovery of tumor-specific DNA methylation markers in the blood makes early treatment possible.

With capabilities in marker discovery, assay development and analytical and clinical validation, we provide total solution as a global diagnostic company

Discovery of tumor-specific DNA methylation markers
in the blood makes early treatment possible.

With capabilities in marker discovery, assay development and
analytical and clinical validation, we provide total solution as a global diagnostic company